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An acute asthma attack is frightening and serious. The common
term for these attacks—“exacerbation,” defined as the worsening
of a disease or an increase in its symptoms—undervalues an
event that is predictive of further acute deterioration and death,
with serious long term consequences, including restriction of
lung growth into adulthood.1 Asthma still kills people of all
ages2; there are preventable factors in the majority of deaths,
and the UK has the highest death rate from asthma in children
and young people in Europe.3 We must do better.
The underlying pathophysiology of an asthma attack is severe
airway obstruction as a result of smooth muscle constriction
and plugging of the airway by inflammatory cells and mucus.
This leads to increased work of breathing and also hypoxaemia
because of ventilation: perfusion (V:Q) mismatch. The signs of
airway narrowing (wheeze) and increased work of breathing
(subcostal recession, use of accessory muscles) are readily
apparent and are often the focus of treatment, but hypoxaemia
may be difficult to detect clinically, at least initially, and is thus
easily forgotten.
The mainstay of treatment is β2 agonists. These were
traditionally delivered by nebuliser until overwhelming evidence
showed that spacers were equally if not more effective in mild
to moderate attacks,4 and (particularly relevant to low and middle
income settings) homemade spacers were just as good as
commercial ones.5 Spacers are now used routinely in emergency
departments, but primary care has been slower to move away
from nebulisers, which can cause harm, particularly when driven
by air.
When treating an asthma attack, it is important to remember the
harms as well as the benefits of short acting β2 agonists.
However delivered, inhaled β2 agonists are absorbed from the
bronchial tree, the oropharynx, and possibly the upper
gastrointestinal tract into the systemic circulation. The response
to alveolar hypoxia is vasoconstriction, and systemic
administration or absorption of β2 agonists may reverse this,
potentially worsening V:Q mismatch and hypoxaemia.
Treatment of a severe attack must include both β2 agonists and
oxygen, so nebulisers driven by air may worsen hypoxaemia.
More rarely, even oxygen driven nebulisers may have the same
effect in children with focal consolidation.6
The nebuliser is not yet ready for the therapeutic junk heap,
however. In very severe asthma, continuous nebulised
salbutamol, sometimes with an intravenous loading dose and
always with oxygen administration, is a valuable strategy for
patients being closely monitored in high dependency settings.7
It is also reasonable to use an oxygen driven nebuliser for any
severe attack in primary care, but only while waiting for
emergency services.
The appropriate choice of delivery device in either primary or
secondary care depends on accurate differentiation of severe
attacks from the rest—and a failure to recognise a life
threatening attack is a recurring theme in national reviews of
asthma deaths.2 The UK and Global Initiative for Asthma
(GINA) guidelines both have helpful tables that define the
population of patients at risk and the clinical findings associated
with a severe attack.8 9 The clinician must track symptoms and
signs in response to treatment, and assessment should include
pulse oximetry.
Assessing patients without objectively measuring oxygen
saturation is unacceptable in any setting given that pulse
oximeters can be obtained cheaply and easily with probes
appropriate for every age; that cyanosis may be difficult to
detect, especially in a poorly lit room in the community; and
that hypoxaemia can be lethal. There is a theoretical risk that
uncontrolled high flow oxygen can lead to serious hypercapnia
even in young adults with asthma.10 But for short term treatment
in primary care, where there may be no ability to titrate oxygen,
it is far better to err on the side of caution and correct
hypoxaemia without worrying about hypercapnia.
In summary, the age old message remains that doctors must
assess patients with an asthma attack using objective
measurements, administer β2 agonists with a device appropriate
to severity, and monitor the response to treatment. In primary
care, nebulisers should be reserved for severe or life threatening
attacks, as a temporary rescue strategy before transfer to hospital.
Importantly, an asthma attack must trigger a focused strategy
to reduce the risk of further attacks, including specialist referral
if attacks are frequent. Clinicians, patients, and family members
should review what went wrong, whether treatment should be
modified, and how best to prevent further events. It is of course
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essential to stop people dying from acute asthma attacks, but
we as a community need to go to the next level, move from
reaction to prevention, and make asthma attacks a real never
event.11
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